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Measuring changes in -cell mass in vivo during progression of diabetes 
mellitus is important for understanding the pathogenesis, facilitating early diagnosis, 
and developing novel therapeutics for this disease. However, a non-invasive method has 
not been developed. A novel series of mitiglinide derivatives (o-FMIT, m-FMIT and 
p-FMIT; FMITs) were synthesized and their binding affinity for the sulfonylurea 
receptor 1 (SUR1) of pancreatic islets were evaluated by inhibition studies. 
(+)-(S)-o-FMIT had the highest affinity of our synthesized FMITs (IC50 = 1.8 M). 
(+)-(S)-o-[
18
F]FMIT was obtained with radiochemical yield of 18% by radiofluorination 
of racemic precursor 7, hydrolysis, and optical resolution with chiral HPLC; its 
radiochemical purity was >99%. In biodistribution experiments using normal mice, 
(+)-(S)-o-[
18
F]FMIT showed 1.94 ± 0.42 %ID/g of pancreatic uptake at 5 min p.i., and 
decreases in radioactivity in the liver (located close to the pancreas) was relatively rapid. 
Ex vivo autoradiography experiments using pancreatic sections confirmed accumulation 
of (+)-(S)-o-[
18
F]FMIT in pancreatic-cells. These results suggest that 
(+)-(S)-o-[
18
F]FMIT meets the basic requirements for an radiotracer, and could be a 
candidate positron emission tomography tracer for in vivo imaging of pancreatic -cells. 









The International Diabetes Federation has reported that the total number of 
people with diabetes mellitus will rise from 285 million in 2009 to 435 million in 2030. 
There are two major types of diabetes mellitus: type-1 diabetes (T1D) and type-2 
diabetes (T2D) [1]. T1D is characterized by selective destruction of -cells by the 
autoimmune reaction, and pancreatic-cell mass (BCM) in T1D is already lost at 
disease onset. T2D is characterized by the decreased ability to secrete insulin and 
increased insulin resistance, it also has been reported that BCM in T2D is decreased 
significantly [2–5]. Recently, incretin-related drugs were reported to have proliferative 
and anti-apoptotic effects on pancreatic -cells in in vitro or rodent experiments [6–8]. 
However, to date, non-invasive quantification of BCM has not been possible, so how 
and when a decrease in BCM begins and whether incretin-related drugs preserve BCM 
in humans is not known. Therefore, a non-invasive method for BCM measurement is 
required urgently for understanding the pathogenesis, facilitating early diagnosis, and 
developing novel therapeutics for diabetes. 
Sulfonylurea (SU) agents are insulin secretagogues, and are used widely in 
T2D treatment. They close the adenosine triphosphate-sensitive potassium ion channel 
(KATP channel) in the pancreatic -cell membrane, thereby depolarizing the cell and 
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triggering insulin secretion [9]. The KATP channel is an octameric complex of two 
protein subunits, an inwardly rectifying K
+
 (Kir6.x) ion channel and a sulfonylurea 
receptor (SUR), which is the target for SU agents [9,10]. The pancreatic -cell KATP 
channel is composed of Kir6.2 and SUR1 subunits [11]. Other KATP channels comprise 
Kir6.2 and SUR2A (heart muscle and skeletal muscle), Kir6.2 and SUR2B (smooth 
muscle), and Kir6.1 and SUR2B (vascular smooth muscle) [9]. In recent years, SUR2B 
expression in human liver tissue has been described [12]. 
Several radiolabeled tracers based on the core structure of SU agents have been 
developed as imaging probes for SUR1 (Figure 1) in recent years [13–18]. However, 
these imaging probes are not available because of low uptake in pancreatic tissue and 
high uptake in liver tissue located close to the pancreas. Promising candidates for 
pancreatic -cell imaging tracers based on SU agents need to have relatively low 
lipophilicity and have high affinity for SUR1. In this context, mitiglinide is a promising 
candidate because of its low lipophilicity (calculated logD (clogD) value (pH 7.4) for 
mitiglinide, −0.29; glibenclamide, 1.14; repaglinide: 1.99) and high affinity and 
selectivity for SUR1 (SUR1/Kir6.2: 3.8 nM, SUR2A/Kir6.2: 3200 nM, SUR2B/Kir6.2: 
4600 nM) [19]. 









F]FMIT] and evaluated their potential as 
in vivo pancreatic -cell imaging tracers (Figure 2). 
 
Figure 1. 
Figure 2.  
 
2. Results and discussion 
2.1. Chemistry 
The synthesis of mitiglinide derivatives containing fluorine (o-, m- and 
p-FMIT) is shown in Scheme 1. The succinic acid derivatives 2a–c were prepared, 
using a method based on the synthetic strategy reported by Kamijo et al. [20], by 
cross-aldol condensation of the benzaldehydes 1a, b, and c (which have a benzyloxy 
group at the o-, m-, and p-position, respectively) with dimethyl succinate in the presence 
of potassium hydroxide, followed by hydrolysis of the ester. Acids 2a–c were treated 
with acetic anhydride in dichloromethane to afford the cyclic acid anhydride derivatives, 
followed by amidation with 3a,4,7,7a-tetrahydroisoindoline (3) and successive 
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esterification to afford the amides 4a–c. Catalytic hydrogenation of 4a–c gave the 
phenols 5a–c. Finally, 5a–c were alkylated with 2-fluoroethyl tosylate in the presence of 
cesium carbonate in DMF, followed by saponification with aqueous sodium hydroxide 
in 1,4-dioxane to give (±)-FMIT. Optical resolution using HPLC with a chiral column 
gave enantiomerically pure (+)-FMIT and (−)-FMIT (o-, m- and p-, respectively). 
 
Scheme 1.  
 
2.2. In vitro Binding Assays 
The FMITs were evaluated using dispersed islet cells from ddY mice pancreas. 
The binding of [
3
H]glibenclamide was displaced by (+)-o-FMIT, (+)-m-FMIT, and 
(−)-p-FMIT in a concentration-dependent manner, similar to mitiglinide Ca2+ (Figure 3). 
The results of these assays are summarized in Table 1. IC50 values of (+)-o-FMIT, 
(+)-m-FMIT, and ()-p-FMIT were 1.8 M, 14.0 M, and 10.7 M, respectively. 
Namely, (+)-o-FMIT had the highest binding affinity for pancreatic islet SUR1 in our 
synthesized FMITs, but its affinity was lower than that of mitiglinide. The other 





Figure 3.  
Table 1.  
2.3. Stereochemistry 
The absolute configuration of (+)-o-FMIT and (−)-o-FMIT was determined by 
1
H-NMR spectra using corresponding -methoxy--(trifluoromethyl)phenylacetic acid 
(MTPA) esters with Eu(fod)3 [21–24]. (+)-o-FMIT and (−)-o-FMIT were transformed 
into corresponding diastereomeric esters 6 by reduction of the carboxyl group and 
esterification according to the method of Dale et al. [25,26]. The magnitude of the 
lanthanide-induced shift (LIS) by Eu(fod)3 for the methoxyl group of 6 in 
1
H-NMR 
indicated that the configuration of (+)-o-FMIT was S and that of (−)-o-FMIT was R 
(Scheme 2). The result of the binding affinity for pancreatic -cell SUR1 of each 
enantiomer suggested that the S-configuration of o-FMIT (which has the same absolute 
configuration as mitiglinide) was important for binding affinity.  
 





The preparation of precursor 7 and its radiofluorination, shown in Scheme 3, 
were undertaken to obtain 
18
F-labeled (+)-(S)-o-FMIT. The phenol 5a, with a phenolic 
hydroxyl group at the o-position, was alkylated with 2-bromoethyl tosylate to give the 
bromo derivative 7. Although we attempted to label the chiral 7 (given by optical 
resolution) with 
18
F, we found that the resulting o-[
18
F]FMIT was racemized. Therefore, 
racemic 7 was used as a precursor, treated with [
18
F]KF and Kryptofix222 in acetonitrile 
at 140 °C in a sealed tube, to afford the 
18
F-labeled methyl ester. This was saponified 
successively with an aqueous solution of sodium hydroxide in 1,4-dioxane. Then, 
optical resolution using HPLC with a chiral column of the racemic o-[
18
F]FMIT gave 
the enantiomerically pure o-[
18
F]FMIT (Figure 4). The radiochemical identity of 
o-[
18
F]FMIT was verified by co-injection HPLC analyses with nonradioactive o-FMIT. 
Each chiral (+)-(S)-o-[
18
F]FMIT showed a single radioactive peak at the same retention 
time as corresponding nonradioactive o-FMIT. The radiochemical yields of 
(+)-(S)-o-[
18
F]FMIT and (‒)-(R)-o-[18F]FMIT were 18% and 13%, respectively. Both of 






Scheme 3.  
Figure 4.  
2.5. Biodistribution Studies 
The tissue time-course distributions of (+)-(S)-o-[
18
F]FMIT in male ddY mice 
are summarized in Table 2. (+)-(S)-o-[
18
F]FMIT showed 1.94 ± 0.42 %ID/g of 
pancreatic uptake at 5 min p.i. and radioactivity washout from the pancreas was 
relatively slow (1.45 ± 0.19 %ID/g at 60 min p.i.). Radioactivity in the liver showed 
rapid clearance (20.83 ± 1.35 %ID/g at 5 min p.i. and 2.18 ± 0.34 %ID/g at 120 min 
p.i.). Radioactivity in the kidney showed rapid clearance (7.77 ± 3.30 %ID/g at 5 min 
p.i. and 1.33 ± 0.30 %ID/g at 120 min p.i.). In addition, radioactivity in the bone was 
low, suggesting that (+)-(S)-o-[
18
F]FMIT was relatively stable to in vivo defluorination.  
 
Table 2.  
 
In the case of (‒)-(R)-o-[18F]FMIT, maximum uptake in the pancreas was 
observed at 5 min p.i. and was 1.18 ± 0.30 %ID/g. Comparison of the two o-[
18
F]FMITs 
at 5, 15 and 60 min p.i. revealed the amount of uptake of (+)-(S)-o-[
18
F]FMIT in the 
pancreas to be approximately double that of (‒)-(R)-o-[18F]FMIT (Figure 5). The 
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difference derived from the presence or absence of the binding affinity for SUR1 would 
suggest the specific binding of (+)-(S)-o-[
18
F]FMIT. Pancreas-to-liver (P/L), 
pancreas-to-kidney (P/K), and pancreas-to-blood (P/B) ratios at different time points are 
shown in Figure 6. The P/L ratio was ≤0.57 at 60 min, the P/K ratio was ≤0.81 at 120 
min, and the P/B ratio was ≤0.64 at 60 min. 
It is considered that the hepatic clearance of (+)-(S)-o-[
18
F]FMIT is relatively 
rapid and that the P/L is high when compared with other radiolabeled compounds based 
on SU agents [14–16]. 
 
Figure 5. 
Figure 6.  
2.6. Ex vivo Autoradiography 
To further characterize the potential of (+)-(S)-o-[
18
F]FMIT as an agent for 
imaging pancreatic -cells, we undertook an ex vivo autoradiography study in normal 
ddY mice (6-week-old, male). Radioactive signals were observed in pancreatic sections, 
whose localizations were relatively consistent with islets colored by insulin 
immunostaining on serial sections, which suggested that (+)-(S)-o-[
18
F]FMIT 
accumulated in pancreatic-cells. However, radioactive signals in other regions were 
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also observed, which suggested non-specific binding of (+)-(S)-o-[
18
F]FMIT (Figure 7).  
 
Figure 7.  
 
3. Conclusions 
We synthesized a novel series of mitiglinide derivatives (o-FMIT, m-FMIT, and 
p-FMIT) and evaluated their binding affinity for pancreatic islet SUR1. (+)-o-FMIT 
showed the highest affinity of our synthesized FMITs, which suggested that introduction 
of a fluoroethoxy group at the o-position affects the affinity less than at other positions. 
In addition, we determined the absolute configuration of each enantiomer of o-FMIT by 
1
H-NMR spectra using MTPA esters with Eu(fod)3, which showed that the exact 




F]FMIT and evaluated its potential as an in vivo 
pancreatic -cell imaging tracer. In in vivo experiments, (+)-(S)-o-[18F]FMIT showed 
pancreatic uptake and relatively rapid clearance in the liver and kidney. The detected 
localization of the radioactive signals by ex vivo autoradiography corresponded with 
that of pancreatic -cells shown by insulin immunostaining.  
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Further enhancements of pancreatic uptake and specific binding to pancreatic 
-cells are required for development of a potential tracer for in vivo imaging of 
pancreatic -cells. Nevertheless, these results provide useful information for targeting 
SUR1 of pancreatic -cells. 
 




F]Fluoride was produced in a cyclotron (CYPRIS HM-18, Sumitomo Heavy 
Industries Ltd., Tokyo, Japan). Radioactivity was measured with an IGC-7 curiemeter 
(Aloka, Tokyo, Japan), an Atomlab100+ (Biodex Medical Systems Inc., Shirley, NY, 
USA) or CRC-15BETA (Capintec Inc., Ramsey, NJ, USA) dose calibrator or a Wallac 
1480 WIZARD 3′′ (PerkinElmer Inc., Waltham, MA, USA) -counter. 
1
H-NMR spectra were obtained on a JEOL JNM-ECS400 (400 MHz) 
spectrometer (JEOL, Tokyo, Japan). Chemical shifts were reported in ppm using 
tetramethylsilane or residual solvent as the internal reference. Infrared (IR) spectra 
were recorded on an FTIR-8300 diffraction grating infrared spectrophotometer 
(Shimadzu, Kyoto, Japan). Mass spectra (MS) were determined on a JEOL JMS-SX 
102A QQ or a JEOL JMS-GC-mate mass spectrometer (JEOL). Silica gel column 
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chromatography was undertaken using a W-Prep 2XY system (Yamazen, Osaka, 
Japan) using a Hi Flash
TM
 40 mm 60 Å silica gel column (Yamazen). Kieselgel 60 
F-254 plates (0.25 mm; Merck, Darmstadt, Germany) were used for thin-layer 
chromatography (TLC). Preparative thin-layer chromatography (PTLC) was conducted 
with a silica gel 60 F-254 plate (0.5 mm; Merck). An LC-20AD system (Shimadzu) 
was used for high-performance liquid chromatography (HPLC), with SPD-20A 
(Shimadzu) ultraviolet (UV;  = 254 nm) and NDW-351D (Aloka, Tokyo, Japan) 
radioisotope (RI) detectors, and a Cosmosil 5C18-AR-II (10 × 250 mm; Nacalai Tesque, 
Kyoto, Japan) reverse-phase HPLC column and a CHIRALPAK AY-H (10 × 250 mm; 
Daicel, Tokyo, Japan) chiral HPLC column. Specific rotations were recorded using a 
SEPA-500 automatic digital polarimeter (Horiba, Kyoto, Japan). All chemicals used 
were of reagent grade. Calculated logD values were obtained by computational 
methods using ACD/Labs v12.0 (Advanced Chemistry Development, Toronto, ON, 
Canada). 
 
4.2. Animal experiments 
Six-week-old male ddY mice were obtained from Japan SLC (Kyoto, Japan). 
Animal studies were conducted in accordance with institutional guidelines. 
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Experimental procedures were approved by the Animal Care Committee of Kyoto 
University (Kyoto, Japan). 
 
4.3. Synthesis 
4.3.1. Procedure for the preparation of dicarboxylic acids 2a–c 
Potassium hydroxide (2.4 eq) was added to a solution of o-, m-, or 
p-benzyloxybenzaldehyde (1a–c) and dimethyl succinate (3.0 eq) in dimethyl sulfoxide, 
and the mixture stirred for 15 hours at 80 °C. An aqueous solution of sodium hydroxide 
(5 M, 30 mL) was added and the mixture stirred for 5 hours at 120 °C. After the reaction, 
distilled water was added to the reaction mixture, which was then washed with ethyl 
acetate. The aqueous layer was acidified with 6 N hydrochloric acid, and extracted with 
ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, 
and evaporated under vacuum to give a pale-yellow solid. The solid was washed with 
hot water and dried to afford dicarboxylic acids 2a–c. 
 
2-(2-Benzyloxybenzylidene)succinic acid (2a) 
The reaction was carried out with o-benzyloxybenzaldehyde (1a) (5.00 g, 23.6 
mmol) in dimethyl sulfoxide (24 mL) to afford 2a (2.98 g, 40%). mp 216–217 °C 
(recrystallized from ethyl acetate). 
1
H-NMR (DMSO-d6) : 3.30 (2H, s), 5.17 (2H, s), 
17 
 
7.00 (1H, t, J = 7.7 Hz), 7.14 (1H, d, J = 8.5 Hz), 7.26–7.45 (7H, m), 7.86 (1H, s), 12.47 
(2H, br s). IR (KBr) : 3042, 2934, 2872, 2540, 2361, 2341, 1697, 1630, 1452, 1420, 
1290, 1232 cm
−1
. EI-MS m/z: 312 (M
+
). HRMS m/z: 312.1002 (Calcd for C18H16O5: 
312.0997). Anal. Calcd for C18H16O5: C, 69.22; H, 5.16. Found: C, 69.28; H, 5.20. 
 
2-(3-Benzyloxybenzylidene)succinic acid (2b) 
The reaction was carried out with m-benzyloxybenzaldehyde (1b) (7.50 g, 35.3 
mmol) in dimethyl sulfoxide (30 mL) to afford 2b (3.84 g, 35%). mp 197–198 °C 
(recrystallized from ethyl acetate). 
1
H-NMR (DMSO-d6) : 3.40 (2H, s), 5.16 (2H, s), 
7.01–7.09 (3H, m), 7.35–7.50 (6H, m), 7.75 (1H, s), 12.60 (2H, br s). IR (KBr) : 2955, 
2866, 2544, 1703, 1678, 1578, 1431, 1267, 1225 cm
−1
. EI-MS m/z: 312 (M
+
). HRMS 
m/z: 312.0990 (Calcd for C18H16O5: 312.0997). Anal. Calcd for C18H16O5: C, 69.22; H, 
5.16. Found: C, 69.14; H, 5.20. 
 
2-(4-Benzyloxybenzylidene)succinic acid (2c) 
The reaction was undertaken with p-benzyloxybenzaldehyde (1c) (5.00 g, 23.5 
mmol) in dimethyl sulfoxide (30 mL) to afford 2c (2.80 g, 38%). mp 207–208 °C 
(recrystallized from ethyl acetate). 
1
H-NMR (DMSO-d6) : 3.44 (2H, s), 5.18 (2H, s), 
7.13 (2H, d, J = 8.8 Hz), 7.14–7.51 (7H, m), 7.73 (1H, s), 12.51 (2H, br s). IR (KBr) : 
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2918, 2849, 2540, 1703, 1674, 1605, 1512, 1425, 1258, 1231, 1175 cm
−1
. EI-MS m/z: 
312 (M
+
). HRMS m/z: 312.1004 (Calcd for C18H16O5: 312.0997). Anal. Calcd for 
C18H16O5: C, 69.22; H, 5.16. Found: C, 69.05; H, 5.22. 
 
4.3.2. Procedure for the preparation of methyl esters 4a–c 
Acetic anhydride (2.0 eq) was added to a solution of acids 2a–c in 
dichloromethane (40 mL), which was stirred for 1.5 hours at 60 °C. The reaction 
mixture was evaporated under vacuum, and dichloromethane (6 mL) added to give a 
suspension. A solution of 3 (1.0 eq) in dichloromethane (4 mL) at 0 °C was added to this 
suspension, and the mixture stirred for 5 hours at room temperature. After the reaction, 
the mixture was evaporated and dissolved in methanol (20 mL). Thionyl chloride (1.5 
mL) at 0 °C was added to this solution, and the mixture stirred for 15.5 hours at room 
temperature. The reaction mixture was evaporated, poured into a saturated aqueous 
solution of sodium bicarbonate and extracted with ethyl acetate. The organic layer was 
washed with brine, dried over magnesium sulfate, and evaporated under vacuum. The 
residue was purified using silica gel column chromatography (n-hexane/ethyl acetate = 





yl) butanoate (4a) 
The reaction was carried out with 2a (2.83 g, 9.06 mmol) to afford 4a (2.87 g, 
73%). 
1
H-NMR (CDCl3) : 1.68 (2H, m), 2.23–2.32 (3H, m), 2.43 (1H, m), 3.29 (1H, 
dd, J = 6.9, 9.6 Hz), 3.40 (1H, m), 3.42 (2H, s), 3.53–3.61 (2H, m), 3.80 (3H, s), 5.14 
(2H, s), 5.65 (2H, m), 7.27–7.42 (6H, m), 7.55 (1H, br d, J = 7.1 Hz), 8.10 (1H, s). IR 
(CHCl3) : 3007, 2949, 1705, 1634, 1485, 1449, 1437, 1242 cm
−1
. FAB-MS m/z: 432 
(M+H
+
). HRMS m/z: 432.2172 (Calcd for C27H29NO4: 432.2175). 
 
Methyl 2-(3-benzyloxybenzylidene)-4-oxo-4-(cis-3a,4,7,7a-tetrahydro-isoindolin-2- 
yl) butanoate (4b) 
The reaction was undertaken with 2b (3.00 g, 9.61 mmol) to afford 4b (1.85 g, 
45%). 
1
H-NMR (CDCl3) : 1.87–1.95 (2H, m), 2.20–2.33 (3H, m), 2.42 (1H, m), 3.28 
(1H, dd, J = 6.8, 9.6 Hz), 3.37 (1H, dd, J = 5.5, 11.7 Hz), 3.41 (2H, s), 3.54 (1H, dd, J = 
6.4, 11.7 Hz), 3.57 (1H, dd, J = 6.8, 9.6 Hz), 3.80 (3H, s), 5.05 (2H, s), 5.63 (2H, m), 
6.94 (1H, dd, J = 2.1, 8.2 Hz), 7.02 (1H, d, J = 7.6 Hz), 7.09 (1H, br), 7.24–7.41 (6H, 
m), 7.85 (1H, s). IR (CHCl3) : 3007, 2951, 1709, 1636, 1437, 1242 cm
−1
. EI-MS m/z: 
431 (M
+





yl) butanoate (4c) 
The reaction was carried out with 2c (3.00 g, 9.61 mmol) to afford 4c (2.89 g, 
70%). 
1
H-NMR (CDCl3) : 1.89–1.98 (2H, m), 2.23–2.36 (3H, m), 2.46 (1H, m), 3.34 
(dd, 1H, J = 7.0, 9.5 Hz), 3.40 (1H, dd, J = 5.3, 11.7 Hz), 3.46 (2H, br s), 3.56 (1H, dd, 
J = 6.2, 11.7 Hz), 3.63 (1H, dd, J = 6.8, 9.5 Hz), 3.79 (3H, s), 5.08 (2H, s), 5.67 (2H, m), 
6.97 (2H, d, J = 8.8 Hz), 7.31–7.45 (7H, m), 7.87 (1H, s). IR (CHCl3) : 3007, 2949, 
1703, 1636, 1437, 1244 cm
−1
. EI-MS m/z: 431 (M
+
). HRMS m/z: 431.2091 (Calcd for 
C27H29NO4: 431.2096). 
 
4.3.3. Procedure for the preparation of phenol 5a–c 
A catalytic amount of 10% Pd-C was added to a solution of 4a–c in methanol 
and the mixture stirred for 10–40 hours under a hydrogen atmosphere (1 atom). The 
mixture was filtered through Hyflo Super-Cel
®
 and the filtrate evaporated under 
vacuum. The residue was purified using silica gel column chromatography 






The reaction was undertaken with 4a (3.05 g, 7.07 mmol) and 10% Pd-C 
(306.7 mg), in methanol (40 mL) for 10 hours to afford 5a (2.18 g, 89%). Two rotamers 
were observed (ca. 1/1). 
1
H-NMR (CDCl3) : 1.40–1.63 (8H, m), 2.21 (1H, m), 2.30 
(1H, m), 2.51 (1H, m), 2.65 (1H, m), 2.95 (2H, m), 3.12 (1H, m), 3.26 (1H, m), 
3.39–3.48 (3H, m), 3.646 and 3.648 (each 1.5H, s), 6.76 (1H, t, J = 7.6 Hz), 6.90 (1H, 
br d, J = 8.0 Hz), 7.05 (1H, br d, J = 7.6 Hz), 7.11 (1H, m), 8.94 and 8.95 (each 0.5H, s). 
IR (CHCl3) : 3215, 2934, 2859, 1732, 1620, 1582, 1489, 1458, 1242 cm
−1
. EI-MS m/z: 
345 (M
+




The reaction was carried out with 4b (151.9 mg, 0.35 mmol) and 10% Pd-C 
(15.2 mg) in methanol (4 mL) for 10 hours to afford 5b (75.5 mg, 62%). Two rotamers 
were observed (ca. 1/1). 
1
H-NMR (CDCl3) : 1.35–1.55 (8H, m), 2.05–2.29 (3H, m), 
2.65 (2H, m), 3.11 (1.5H, m), 3.27–3.45 (4.5H, m), 3.68 and 3.69 (each 1.5H, s), 6.64 
(1H, br d, J = 7.3 Hz), 6.72 (1H, m), 6.94 (1H, s), 7.09–7.14 (1H, m), 7.94 (1H, m). IR 
(CHCl3) : 3302, 2932, 2859, 1728, 1624, 1599, 1456, 1240 cm
−1
. EI-MS m/z: 345 (M
+
). 






The reaction was undertaken with 4c (161.5 mg, 0.37 mmol) and 10% Pd-C 
(16.2 mg), in methanol (4 mL) for 40 hours to afford 5c (127.7 mg, 99%). Two rotamers 
were observed (ca. 1.5/1). 
1
H-NMR (CDCl3) : 1.33–1.61 (8H, m), 2.15 (1H, m), 
2.21–2.32 (2H, m), 2.66 (2H, m), 2.96 (0.6H, dd, J = 4.9, 6.4 Hz), 2.99 (0.4H, dd, J = 
4.9, 6.4 Hz), 3.17 (0.6H, dd, J = 6.2, 10.1 Hz), 3.24–3.47 (4.4H, m), 3.65 (1.8H, s), 3.66 
(1.2H, s), 6.75 (2H, m), 6.96–7.04 (3H, m). IR (CHCl3) : 3312, 2932, 1728, 1626, 
1516, 1450, 1258, 1173 cm
−1
. EI-MS m/z: 345 (M
+
). HRMS m/z: 345.1946 (Calcd for 
C20H27NO4: 345.1940). 
 
4.3.4. Procedure for the preparation of FMIT 
Step 1: Cesium carbonate (1.4 eq) was added to a solution of 5a–c and 
2-fluoroethyl tosylate (1.5 eq) in dimethyl formamide, and the mixture stirred at 60 °C. 
After chilling the reaction mixture to room temperature, the mixture was poured into 
water and extracted with diethyl ether. The organic layer was washed with a small 
amount of water, dried over magnesium sulfate, and evaporated under vacuum. The 
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residue was purified using silica gel column chromatography (n-hexane/ethyl acetate = 
1/1) to afford the methyl ester. 
Step 2: An aqueous solution of sodium hydroxide (2 M) was added to a 
solution of the methyl ester in 1,4-dioxane, and the mixture stirred at 50 °C. After 
chilling the reaction mixture to room temperature, it was acidified with 1 N 
hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with 
brine, dried over magnesium sulfate, and evaporated under vacuum. The residue was 




tanoicacid (o-FMIT)  
The step-1 reaction was carried out with 5a (386.9 mg, 1.12 mmol) in dimethyl 
formamide (10 mL) for 17.5 hours to afford the corresponding methyl ester (386.0 mg, 
88%). The step-2 reaction was undertaken with the methyl ester (386.0 mg, 0.99 mmol) 
and an aqueous solution of sodium hydroxide (2 M, 5 mL) in 1,4-dioxane (20 mL) for 1 
hour to afford o-FMIT (315.4 mg, 85%). Two rotamers were observed (ca. 1/1). 
1
H-NMR (CDCl3) : 1.34–1.61 (8H, m), 2.18 (2H, m), 2.53 (2H, m), 2.85 (1H, m), 2.93 
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(0.5H, dd, J = 5.7, 10.5 Hz), 3.06–3.28 (3.5H, m), 3.32 (0.5H, dd, J = 6.0, 12.1 Hz), 
3.38 (1H, m), 3.43 (0.5H, dd, J = 7.1, 12.1 Hz), 4.22 (2H, br d, J = 27.5 Hz), 4.76 (2H, 
dt, J = 3.4, 47.4 Hz), 6.85 (1H, d, J = 8.2 Hz), 6.92 (1H, t, J = 7.3 Hz), 7.16 (1H, d, J = 
7.6 Hz), 7.21 (1H, t, J = 7.6 Hz). IR (CHCl3) : 3007, 2934, 2859, 1732, 1587, 1495, 
1450, 1242 cm
−1
. FAB-MS m/z: 378 (M+H
+
). HRMS m/z: 378.2076 (Calcd for 
C21H29FNO4: 378.2081). 
Racemic o-FMIT was optically resolved using preparative HPLC 
(acetonitrile/methanol/TFA = 95/5/0.1, 2.0 mL/min) using a chiral column. The 
enantiomer with a retention time of 11.6 min was (+)-o-FMIT, and the enantiomer with 
a retention time of 24.3 min was (−)-o-FMIT. (+)-o-FMIT: []
25
D = + 6.9° (c 1.01, 
MeOH). (−)-o-FMIT: []
25
D = −5.7° (c 0.30, MeOH). 
 
2-(3-Fluoroethyloxybenzyl)-4-(cis-3a,4,5,6,7,7a-hexahydro-isoindolin-2-yl)-4-oxobu
tanoic acid (m-FMIT)  
The step-1 reaction was carried out with 5b (65.6 mg, 0.19 mmol) in dimethyl 
formamide (2 mL) for 13 hours to afford the corresponding methyl ester (56.1 mg, 76%). 
The step-2 reaction was undertaken with the methyl ester (56.1 mg, 0.14 mmol) and an 
aqueous solution of sodium hydroxide (2 M, 1 mL) in 1,4-dioxane (4 mL) for 1 hour to 
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afford m-FMIT (37.9 mg, 72%). Two rotamers were observed (ca. 1/1). 
1
H-NMR 
(CDCl3) : 1.35–1.56 (8H, m), 2.20 (2H, m), 2.42–2.59 (2H, m), 2.77 (1H, m), 3.03 
(0.5H, dd, J = 6.0, 10.0 Hz), 3.11–3.23 (3.5H, m), 3.33 (0.5 H, dd, J = 6.0, 12.0 Hz), 
3.38 (1H, m), 3.45 (0.5H, dd, J = 6.8, 12.0 Hz), 4.20 (2H, dt, J = 4.4, 28.0 Hz), 4.74 (2H, 
dt, J = 4.4, 47.2 Hz), 6.78 (3H, m), 7.22 (1H, br t, J = 7.6 Hz), 12.05 (1H, br). IR 





). HRMS m/z: 378.2084 (Calcd for C21H29FNO4: 378.2081). 
Racemic m-FMIT was optically resolved using preparative HPLC 
(acetonitrile/methanol/TFA = 95/5/0.1, 2.0 mL/min) using a chiral column. The 
enantiomer with a retention time of 12.5 min was (−)-m-FMIT, and the enantiomer with 
a retention time of 44.6 min was (+)-m-FMIT. (+)-m-FMIT: []
25
D = +1.8° (c 1.88, 
MeOH). (−)-m-FMIT: []
25
D = −1.7° (c 2.52, MeOH). 
 
2-(4-Fluoroethyloxybenzyl)-4-(cis-3a,4,5,6,7,7a-hexahydro-isoindolin-2-yl)-4-oxobu
tanoic acid (p-FMIT)  
The step-1 reaction was undertaken with 5c (57.6 mg, 0.17 mmol) in dimethyl 
formamide (2 mL) for 21 hours to afford the corresponding methyl ester compound 
(48.5 mg, 73%). The step-2 reaction was carried out with the methyl ester (56.1 mg, 
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0.14 mmol) and an aqueous solution of sodium hydroxide (2 M, 1 mL) in 1,4-dioxane (4 
mL) for 1 hour to afford p-FMIT (15.8 mg, 35%). Two rotamers were observed (ca. 1/1). 
1
H-NMR (CDCl3) : 1.35–1.55 (8H, m), 2.18 (2H, m), 2.38 (1H, dd, J = 4.4, 16.4 Hz), 
2.55 (1H, dd, J = 6.0, 16.4 Hz), 2.75 (1H, dd, J = 8.8, 13.6 Hz), 3.04–3.40 (6H, m), 4.16 
(2H, dt, J = 4.0, 28.4 Hz), 4.73 (2H, dt, J = 4.0, 47.6 Hz), 6.84 (2H, d, J = 8.0 Hz), 7.12 
(2H, d, J = 8.0 Hz), 11.62 (1H, br). IR (CHCl3) : 3007, 2934, 2859, 1732, 1585, 1512, 
1452, 1240, 1180 cm
−1
. EI-MS m/z: 377 (M
+
). HRMS m/z: 377.2008 (Calcd for 
C21H28FNO4: 377.2002). 
Racemic p-FMIT was optically resolved using preparative HPLC 
(acetonitrile/methanol/TFA = 95/5/0.1, 2.0 mL/min) using a chiral column. The 
enantiomer with a retention time of 17.4 min was (−)-p-FMIT, and the enantiomer with 
a retention time of 28.8 min was (+)-p-FMIT. (+)-p-FMIT: []
25
D = +12.2° (c 3.72, 
MeOH). (−)-p-FMIT: []
25
D = ° (c 3.74, MeOH). 
 
4.3.5. Procedure for the preparation of MTPA esters (S,R)-6 and (R,R)-6. 
Isobutyl chloroformate (2.0 eq) was added to a solution of triethylamine (2.0 
eq) and (+)-o-FMIT (40.8 mg, 0.11 mmol) or (−)-o-FMIT (40.1 mg, 0.11 mmol) in 
tetrahydrofuran (1 mL), and the mixture stirred for 3 hours at −10 °C. The reaction 
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mixture was filtered, and an aqueous solution of NaBH4 (5 eq) added to the filtrate at 
0 °C. The mixture was stirred for 1 hour at room temperature. After the reaction the 
mixture was poured into a saturated aqueous solution of sodium bicarbonate and 
extracted with ethyl acetate. The organic layer was washed with brine, dried over 
sodium sulfate, and evaporated under vacuum. The residue was purified using 
preparative silica gel TLC (chloroform/methanol = 20/1) to afford the alcohol derived 
from (+)-o-FMIT (11.7 mg, 30%) or the alcohol derived from (−)-o-FMIT (9.8 mg, 
25%). Triethylamine (1.2 eq), a catalytic amount of DMAP, and 
(S)--methoxy--(trifluoromethyl)phenylacetyl chloride (1.2 eq) were added to a 
solution of the alcohol derived from (+)-o-FMIT (11.7 mg, 32.2 mol) or (−)-o-FMIT 
(9.8 mg, 27.0 mol) at 0 °C, and stirred for 5 hours at room temperature. The reaction 
mixture was poured into a saturated aqueous solution of sodium bicarbonate and 
extracted with ethyl acetate. The organic layer was washed with brine, dried over 
sodium sulfate, and evaporated under vacuum. The residue was purified using 
preparative silica gel TLC (n-hexane/ethyl acetate = 1/1) to afford (S,R)-6 (11.3 mg, 





xobutyl (R)--methoxy--(trifluoromethyl)phenylacetate (S,R-6) 
Two rotamers were observed (ca. 1/1). []
25
D  = +23.0° (c 0.55, CHCl3). 
1
H-NMR (CDCl3) : 1.34–1.67 (8H, m), 2.20 (4H, m), 2.75 (3H, br), 3.04 (0.5H, dd, J = 
5.7, 9.8 Hz), 3.08 (0.5H, dd, J = 6.0, 9.8 Hz), 3.15 (0.5H, dd, J = 6.9, 9.8 Hz), 3.23 (0.5 
H, dd, J = 7.1, 9.8 Hz), 3.29–3.41 (2H, m), 3.55 and 3.56 (each 1.5H, s), 4.19 (2H, br d, 
J = 28.2 Hz), 4.27 (1H, m), 4.42–4.48 (1H, m), 4.73 (2H, dt, J = 3.7, 47.4 Hz), 6.82 (1H, 
d, J = 8.2 Hz), 6.88 (1H, br t, J = 7.3 Hz), 7.06 (1H, d, J = 7.3 Hz), 7.18 (1H, t, J = 7.8 
Hz), 7.41 (3H, m), 7.53 (2H, m). IR (CHCl3) : 3007, 2932, 2857, 1748, 1624, 1493, 
1450, 1244, 1194, 1171 cm
−1
. FAB-MS m/z: 580 (M+H
+
). HRMS m/z: 580.2691 (Calcd 
for C31H38F4NO5: 580.2686).  




xobutyl (R)--methoxy--(trifluoromethyl)phenylacetate (R,R-6) 
Two rotamers were observed (ca. 1/1). []
25
D  = +23.9° (c 0.59, CHCl3).
 
1
H-NMR (CDCl3) : 1.35–1.63 (8H, m), 2.16 (4H, m), 2.73 (3H, br), 3.07 (1H, m), 3.20 
(1H, m), 3.31–3.43 (2H, m), 3.55 and 3.56 (each 1.5H, s), 4.20 (2H, br d, J = 27.9 Hz), 
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4.35 (2H, m), 4.74 (2H, dt, J = 3.9, 47.4 Hz), 6.81 (1H, d, J = 8.0 Hz), 6.88 (1H, t, J = 
7.3 Hz), 7.04 (1H, d, J = 7.3 Hz), 7.18 (1H, t, J = 7.8 Hz), 7.41 (3H, m), 7.53 (2H, m). 
IR (CHCl3) : 3007, 2932, 2857, 1748, 1624, 1493, 1450, 1246, 1194, 1171 cm
−1
. 
FAB-MS m/z: 580 (M+H
+
). HRMS m/z: 580.2681 (Calcd for C31H38F4NO5: 580.2686). 
The magnitude of LISOMe vs the molar ratio of Eu(fod)3 for (R,R)-6 was 0.90 
ppm. 
 
NMR studies for determination of absolute configuration 
A solution of MTPA esters 6 in CDCl3 were taken with a molar ratio of Eu(fod)3 to 
MTPA ester of 0.1–0.3 and their NMR spectra recorded. The magnitudes of the induced 
chemical shift of OMe signals were plotted against molar ratio (Eu(fod)3/MTPA ester). 
In this range, the induced shifts were essentially linear with respect to the molar ratio of 
the reagent. The lanthanide-induced shift of 6 derived from (+)-o-FMIT vs molar ratio 
was 0.47 ppm, and that of 6 derived from (−)-o-FMIT was 0.90 ppm. Therefore, 
(+)-o-FMIT was determined to have an S-configuration, and (−)-o-FMIT was 
determined to have a R-configuration. 
 




Cesium carbonate (1.16 g, 3.6 mmol) was added to a solution of 5a (560 mg, 
1.6 mmol) and 2-bromoethyl p-toluenesulfonate (1.09 g, 3.9 mmol) in dimethyl 
formamide (8 mL), and the mixture stirred at 40 °C over one weekend. After chilling the 
reaction mixture to room temperature it was poured into water and extracted with ethyl 
acetate. The organic layer was washed with water and brine, dried over magnesium 
sulfate, and evaporated under vacuum. The residue was purified using silica gel column 
chromatography (n-hexane/ethyl acetate = 4/1 to 1/1) to afford 7 (440 mg, 60%). Two 
rotamers were observed (ca. 1/1).
 1
H-NMR (CDCl3) : 1.34–1.64 (8H, m), 2.14 (1H, m), 
2.22 (1H, m), 2.33 (1H, m), 2.65 (0.5H, dd, J = 5.7, 9.8 Hz), 2.68 (0.5H, dd, J = 5.3, 9.6 
Hz), 2.85 (1H, m), 3.14 (1H, m), 3.17 (0.5H, dd, J = 6.2, 9.8 Hz), 3.26–3.42 (4.5H, m), 
3.63 and 3.64 (each 1.5H, s), 3.69 (2H, br t, J = 4.6 Hz), 4.30 (2H, br t, J = 4.6 Hz), 6.81 
(1H, d, J = 8.2 Hz), 6.90 (1H, br t, 7.3 Hz), 7.11 (1H, d, J = 7.6 Hz), 7.19 (1H, br t, J = 
8.2 Hz). IR (CHCl3) : 3007, 2932, 2859, 1728, 1628, 1493, 1454, 1248, 1194 cm
−1
. 
FAB-MS m/z: 452 (M+H
+
). HRMS m/z: 452.1434 (Calcd for C22H31BrNO4: 452.1436). 
 
4.4. In vitro Binding Assays 
The displacement effect of the mitiglinide derivatives on SUR1 binding was 
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assessed using dispersed islet cells as described previously [27]. Pancreatic islets were 
isolated from male ddY mice by a collagenase digestion method [14]. Isolated islets 
were dispersed using 0.05% trypsin/0.53 mM EDTA (Invitrogen, Carlsbad, CA, USA) 
and PBS. Islet cells were incubated with [
3
H]glibenclamide (3.7 kBq) in 1 mL of buffer 
containing 20 mM HEPES (pH 7.4), 1 mM MgCl2, 1 mg/mL bacitracin, and 1 mg/mL 
BSA for 1 hour at room temperature in the presence of varying concentrations of the 
nonradioactive mitiglinide derivatives. Binding was terminated by rapid filtration 
through Whatman GF/C filters (24 mm) followed by washing thrice with 5 mL of 
ice-cold phosphate-buffered saline (PBS). The radioactivity of the filters was measured 
with a liquid scintillation analyzer. Results were expressed as the percentage of the 
radioactivity of the bound [
3
H]glibenclamide remaining after the addition of the 
nonradioactive compound. GraphPad Prism software (v5.03 for Windows) was used to 












2-yl)-4-oxobutanoic acid ((‒)-(R)-o-[18F]FMIT) 
[
18
F]Fluoride trapped on an anion-exchange cartridge was eluted with an 
aqueous solution of potassium carbonate (33 mM). Kryptofix222 (22.1 mg) was 
dissolved in the solution of [
18
F]fluoride (9.99 GBq) in water. The solvent was removed 
at 120 °C under a stream of nitrogen gas. The residue was dried with anhydrous 
acetonitrile (0.5 mL) thrice at 120 °C under nitrogen. For (+)-(S)-o-[
18
F]FMIT, a 
solution of the precursor 7 (2.83 mg) in acetonitrile (0.15 mL) was added to the reaction 
vessel containing the 
18
F (4.78 MBq). The mixture was heated at 140 °C for 10 min. 
After the solvent was removed at room temperature under a stream of nitrogen gas, the 
residue was dissolved in 1,4-dioxane (0.05 mL), then an aqueous solution of sodium 
hydroxide (2 M, 0.05 mL) was added and the mixture stored for 1 hour at room 
temperature. After this, acetonitrile (0.2 mL) was added and the mixture purified using 
HPLC with a reverse-phase column (Cosmosil 5C18-AR-II, 10 × 250 mm, 
acetonitrile/water/TFA = 70/30/0.1) and a chiral column (CHIRALPAK AY-H, 10 × 250 
mm, acetonitrile/methanol/TFA = 95/5/0.1) at a flow rate of 1.0 mL/min. Fractions 
containing the product were evaporated. (+)-(S)- and (‒)-(R)-o-[18F]FMIT were obtained 
with a radiochemical yield of 18% and 13% (overall decay corrected). The 
radiochemical purity of these radiotracers was >98% after purification by 
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high-performance liquid chromatography (HPLC) and their specific activity estimated 
to be ≈100 GBq/μmol. 
 
4.6. Biodistribution Studies 
Biodistribution studies of (+)-(S)- and (‒)-(R)-o-[18F]FMIT were conducted 
using six-week-old male ddY mice. o-[
18
F]FMITs (0.15–0.22 MBq/100 L) were 
administered to mice through tail-vein injection. At 5, 15, 30, 60, and 120 min after 
administration, mice were sacrificed by exsanguination. Radioactivity in blood and 
organs was measured using an auto well -counter. Radioactivity levels in tissue were 
expressed as a percentage of the injected dose per gram of tissue (% ID/g). 
 
4.7. Ex vivo Autoradiography Experiments 
 (+)-(S)-o-[
18
F]FMIT was administered to non-anesthetized ddY mice (male, 
weight: 20 g, n = 3) by intravenous injection (185 MBq/100 L). Mice were sacrificed 
by exsanguination 30 min after administration. Pancreases were removed, rinsed with 
saline, and frozen immediately. Frozen pancreases were cut into several sections 
(thickness, 10 m), placed on a glass slide, and covered with a glass cover. The 
radioactivity of a pancreatic section on a glass slide was determined using an imaging 
34 
 
analyzer (BAS5000, Fujifilm Photo Film, Tokyo, Japan) (18-hours exposure). 
 
4.8. Immunohistochemistry 
Serial sections of pancreas prepared for autoradiography were fixed with 4% 
paraformaldehyde in 0.1 M phosphate buffer for 1 hour, then permeabilized and blocked 
with 0.5% Triton X-100 in PBS containing 1.5% goat serum for 1 hour at room 
temperature. Specimens were incubated with rabbit anti-insulin (1:50 dilution; Santa 
Cruz Biotechnology, Santa Cruz, CA, USA) as a primary antibody overnight at 4 °C. 
After rinsing with PBS, specimens were incubated with Alexa Fluor 488-labeled goat 
anti-rabbit IgG (1:200; Molecular Probes, Eugene, OR, USA) as a secondary antibody 
for 1 hour at room temperature. Fluorescence signals were acquired through a 
fluorescence microscope (BZ-9000, KEYENCE, Osaka, Japan). 
 
4.9. Statistical Analyses 
Data are the mean ± SD. The statistical significance of differences was 
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Figure 2. Structure of mitiglinide and 
18






Figure 3. Inhibition of [
3
H]glibenclamide binding to islet cells at various concentrations 
of (+)-o-FMIT, (+)-m-FMIT, and (−)-p-FMIT. Specific binding of [3H]glibenclamide 






Figure 4. HPLC chromatograms of (+)-(S)-o-[
18
F]FMIT and (−)-(R)-o-[18F]FMIT. 








Figure 5. Comparative uptake of (+)-(S)- and (−)-(R)-o-[18F]FMIT at 5, 15 and 60 min 






Figure 6. Uptake ratios of (+)-(S)-o-[
18
F]FMIT. (a) pancreas/liver, (b) pancreas/kidney, 




Figure 7. (a) Autoradiography of (+)-(S)-o-[
18
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Mitiglinide ― 0.14 (0.12–0.17) 
o-FMIT 
(+)- 11.6 1.8 (1.2–2.6) 
()- 24.3 N.D. 
m-FMIT 
()- 12.5 14.0 (10.8–18.1) 
(+)- 44.6 N.D. 
p-FMIT 
()- 17.4 10.7 (7.0–16.1) 
(+)- 28.8 N.D. 
a
Retention time using chiral HPLC (CHIRALPAK AY-H, 10 × 250 mm, stationary 
phase acetonitrile/methanol/TFA = 95/5/0.1, flow rate 2.0 mL/min). 
b
Best-fit values and 





 values were >0.85 in experiments used to determine 




Table 2. Tissue distribution of (+)-(S)-o-[
18
F]FMIT in ddY mice 
 
Values are %ID/g (mean ± S.D.) for 5 animals at each interval. 
 
 
 
 
